MetLife’s Adjusted EPS Rose 20%. GAAP Profit Barely Moved.

MetLife’s second-quarter headline was a widening gap between underlying and reported profitability. Total revenue increased to $19.15 billion from $17.34 billion a year earlier, a 10.5% gain. Premiums, fees and other revenue rose 7.1% to $13.65 billion, while net investment income increased 18.4% to $6.70 billion. The supplied quarterly financial table shows pre-tax margin improving to 8.4% from 8.0%, a 40-basis-point increase. These figures are drawn from the MetLife Q2 FY2026 earnings release and the MetLife Q2 FY2026 Form 10-Q.

GAAP earnings moved much less. Net income available to common shareholders increased 1.0% to $705 million, and diluted EPS rose 5.8% to $1.09. Net investment losses of $428 million and net derivative losses of $772 million held down the reported result, partly offset by $270 million of market-risk-benefit remeasurement gains. Management attributed the derivative losses to stronger equity markets, higher long-term interest rates and a stronger U.S. dollar.

Adjusted earnings presented a stronger picture. Adjusted earnings increased 15.5% to $1.57 billion, while adjusted EPS rose 20.3% to $2.43. Management attributed that increase to favorable underwriting and broad-based volume growth. The difference between earnings and per-share growth also reflects repurchases: diluted weighted-average shares declined to 646.9 million from 675.0 million, a 4.2% reduction.

The improvement was broad. Group Benefits adjusted earnings rose 25.4% to $503 million, primarily from favorable underwriting and volume growth. Asia increased 21.4% to $420 million, or 24.6% on a constant-currency basis, aided by stronger equity markets, higher variable investment income and volume. Latin America rose 15.0% to $268 million, EMEA increased 8.0% to $108 million, and MetLife Investment Management rose 5.6% to $57 million. Retirement and Income Solutions grew only 1.9% to $377 million as favorable recurring interest margins and volume were partly offset by lower variable investment income.

Not every cost indicator improved. The adjusted expense ratio excluding notable items and pension-risk transfers increased to 20.8% from 19.8%, while the comparable direct expense ratio rose to 12.1% from 11.7%. Corporate Other’s adjusted loss also widened to $160 million from $142 million. Those changes did not overwhelm operating growth this quarter, but they limit how much of the adjusted earnings increase can be treated as pure operating leverage.

The quarter strengthens the case that MetLife can generate growth across several independent earnings engines. Adjusted premiums, fees and other revenues excluding pension-risk transfers increased 5.0% to $13.01 billion, and management reported growth across every operating segment. That breadth matters for an insurer because underwriting, investment income, currencies and market-sensitive products do not move together consistently.

Adjusted return on equity reached 17.0% for the second consecutive quarter, up from 14.6% a year ago and at the top of management’s stated range. Adjusted book value per share increased 2.6% to $57.71, while reported book value per share rose 7.8% to $38.59. For valuation, adjusted book value is the cleaner anchor because reported equity remains heavily affected by unrealized investment changes, derivative marks and liability discount-rate remeasurement.

Capital deployment added to the operating progress. MetLife repurchased approximately $700 million of shares and paid about $400 million in common dividends during the quarter. Common shares outstanding ended the period at 637.8 million, down 4.3% from 666.8 million a year earlier. Holding-company cash and liquid assets were $3.4 billion, within management’s target range, and total U.S. statutory adjusted capital was expected to be approximately $16.4 billion, up from $16.2 billion at the end of the first quarter.

The offset is that adjusted earnings remain substantially above GAAP earnings. Adjusted earnings of $1.57 billion were more than twice the $705 million available to common shareholders under GAAP. The exclusions are consistent with MetLife’s disclosed methodology, but the gap still matters because market volatility, hedging outcomes and investment losses affect reported equity and capital over time. This was an operationally strong quarter, not a clean one in every accounting measure.

There is no prior SageNoodle fair value to carry forward, so this is the initial post-print valuation. We use adjusted book value because conventional free cash flow and enterprise-value metrics do not translate well to a regulated insurer. The quarter ended with adjusted book value of $57.71 per share and adjusted return on equity of 17.0%, as reported in the MetLife Q2 FY2026 earnings release.

Our base case applies an assumed 1.75-times adjusted-book multiple to $57.71, producing $100.99, rounded to $101 per share. The multiple is an explicit analytical assumption rather than company guidance. It recognizes the 17.0% adjusted return on equity, broad segment growth and continuing repurchases, while retaining a discount for market-sensitive GAAP results, complex liabilities and expense-ratio pressure.

The bear case applies 1.40 times adjusted book value, producing $80.79, rounded to $81. This would fit a scenario in which underwriting normalizes, investment losses persist and the adjusted expense ratio remains elevated. The bull case applies 2.10 times adjusted book value, producing $121.19, rounded to $121, assuming adjusted return on equity remains near 17.0%, volume growth continues and capital returns steadily reduce the share count.

At $96.78, MetLife trades at approximately 1.68 times adjusted book value and 18.5 times trailing GAAP EPS of $5.22. The $101 base value implies 4.4% price upside, which falls within our fairly valued range. The quarter justifies confidence in current adjusted profitability, but not a materially higher multiple without evidence that expense ratios can stabilize and that the gap between adjusted and GAAP earnings can narrow.

The clearest disconfirming signal would be a reversal in underwriting. Group Benefits supplied the largest absolute year-over-year segment increase, adding $102 million of adjusted earnings. If favorable claims experience normalizes faster than volume grows, the strongest contributor to this quarter’s improvement could weaken.

Market and investment outcomes are the second test. Net investment and derivative losses together exceeded $1.2 billion before the other reconciliation items. MetLife described the credit environment as stable, but defaults, downgrades, real-estate impairments or ineffective hedges could pressure GAAP income, book value or statutory capital even if adjusted earnings initially appear resilient.

Expenses are a more immediate operating concern. The adjusted expense ratio excluding notable items and pension-risk transfers rose 100 basis points year over year, and Corporate Other’s loss widened. If revenue growth slows while those costs remain elevated, adjusted earnings growth could fall below the pace implied by this quarter.

Finally, the valuation depends on adjusted book value remaining a credible measure of deployable capital and future earnings power. A material deterioration in statutory capital, reduced subsidiary dividends to the holding company or a pause in repurchases would weaken the per-share compounding argument. Conversely, sustained 17.0% adjusted return on equity with lower expense ratios and a narrower GAAP-adjusted earnings gap would make the bull-case multiple more defensible.